2,6-Dihydroxyacetophenone

2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia^{[1][2][3][4][5][6]}. In Vitro:2,6-Dihydroxyacetophenone (5-40 µM, 48 h) inhibits cell growth and proliferation of HCT8 cells^[1].
2,6-Dihydroxyacetophenone (10-100 µM, 24-48 h) arrests the cell cycle at the G0/G1 phase, induces apoptosis and suppresses cell migration in HCT8 cells^[1].
2,6-Dihydroxyacetophenone (40 µM, 48 h) reduces the expression of p70S6K1 and AKT1 in HCT8 cells^[1].
2,6-Dihydroxyacetophenone (0.1-2 mM) inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM^[2].
2,6-Dihydroxyacetophenone (200 µM, 48 h) decreases the survival rate of BRL 3A cells^[2].
2,6-Dihydroxyacetophenone (0.325-1.3 mM, 24 h) inhibits lipid accumulation in FFA-induced LO2 cells, and 1.3 mM reduces intracellular TG levels^[6].
In Vivo:2,6-dihydroxyacetophenone (40 mM/kg, i.g., daily, 21 days) improves uric acid metabolism disorder in hyperuricemia mice^[4].
2,6-dihydroxyacetophenone (60.86 mg/kg (400 μmol/kg), i.g., twice daily, 3 weeks) decreases plasma cholesterol levels in hypercholesterolemic rats^[5].
2,6-dihydroxyacetophenone (7 mg/kg, i.g., daily, 8 weeks) inhibits lipid accumulation high-fat diet (HFD)-induced obese mice^[6].